Case Name: In re: OMEPRAZOLE PATENT LITIGATION. Astrazeneca AB, Aktiebolaget Hassle, KBI-E, Inc., KBI, Inc., and Astrazeneca LP, Plaintiffs-Appellants, v. Mylan Laboratories, Inc., Mylan Pharmaceuticals, Incorporated, Esteve Quimica, S.A., and Laboratorios Dr. Esteve, S.A., Defendants-Appellees
Court: United States Court of Appeals for the Federal Circuit
Jurisdiction: United States
Decision Date: 2008-02-14
Citations: 269 F. App'x 970
Docket Number: Nos. 2007-1476, 2007-1477, 2007-1478
Parties: In re: OMEPRAZOLE PATENT LITIGATION. Astrazeneca AB, Aktiebolaget Hassle, KBI-E, Inc., KBI, Inc., and Astrazeneca LP, Plaintiffs-Appellants, v. Mylan Laboratories, Inc., Mylan Pharmaceuticals, Incorporated, Esteve Quimica, S.A., and Laboratorios Dr. Esteve, S.A., Defendants-Appellees.
Judges: 
Reporter: West's Federal Appendix
Volume: 269
Pages: 970–971

Head Matter:
In re: OMEPRAZOLE PATENT LITIGATION. Astrazeneca AB, Aktiebolaget Hassle, KBI-E, Inc., KBI, Inc., and Astrazeneca LP, Plaintiffs-Appellants, v. Mylan Laboratories, Inc., Mylan Pharmaceuticals, Incorporated, Esteve Quimica, S.A., and Laboratorios Dr. Esteve, S.A., Defendants-Appellees.
Nos. 2007-1476, 2007-1477, 2007-1478.
United States Court of Appeals, Federal Circuit.
Feb. 14, 2008.

Opinion:
ORDER
Appellant having filed the required brief, it is
ORDERED that the order of dismissal and the mandate be, and the same hereby are, VACATED and RECALLED, and the notice of appeal is REINSTATED.